Literature DB >> 448526

Pathogenesis of rickets in chronic hepatobiliary disease in children.

S W Kooh, G Jones, B J Reilly, D Fraser.   

Abstract

To investigate whether hepatobiliary rickets is caused by defective intestinal absorption of vitamin D or by impaired hepatic hydroxylation of the vitamin, we studied three children who developed severe rickets, hypocalcemia, and hypophosphatemia, two despite having received 400 to 800 IU vitamin D per day by mouth, and one despite prolonged treatment with 10,000 IU daily. On oral vitamin D therapy, plasma vitamin D and 25-hydroxyvitamin D levels were low. When two children were treated with weekly intravenous doses of 3,000 IU vitamin D to approximate the recommended prophylactic allowance, their plasma calcium and phosphate values improved promptly, the radiographic lesions healed, and the plasma concentrations of vitamin D and 25-hydroxyvitamin D became normal. Our studies indicate that the primary cause of hepatobiliary rickets is intestinal malabsorption of vitamin D, not impairment of the hepatic metabolism of the vitamin.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 448526     DOI: 10.1016/s0022-3476(79)80204-8

Source DB:  PubMed          Journal:  J Pediatr        ISSN: 0022-3476            Impact factor:   4.406


  4 in total

Review 1.  Hepatic osteodystrophy: vitamin D metabolism in patients with liver disease.

Authors:  J E Compston
Journal:  Gut       Date:  1986-09       Impact factor: 23.059

2.  Bone mineral analysis and X-ray examination of the bone in patients with biliary atresia.

Authors:  K Ohshima; Y Kubo; N Samejima
Journal:  Jpn J Surg       Date:  1990-09

3.  Transient hyperthyroxinemia associated with rickets.

Authors:  A K Leung
Journal:  J Natl Med Assoc       Date:  1988-05       Impact factor: 1.798

4.  Effects of phenobarbital on biliary lipid metabolism in children with chronic intrahepatic cholestasis.

Authors:  M Becker; K von Bergmann; H W Rotthauwe; O Leiss
Journal:  Eur J Pediatr       Date:  1984-11       Impact factor: 3.183

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.